Experimental Drug Shows Promise for Psychosis in Alzheimer's Disease
A phase 2 trial called RADIANT found that once-daily remlifanserin reduced psychosis symptoms in Alzheimer's patients. The drug's safety profile resembled placebo, supporting progression to larger studies. These results could lead to a new treatment option for this challenging condition.
The RADIANT trial, a phase 2 study, evaluated remlifanserin as a once-daily treatment for psychosis in people with Alzheimer's disease. Results showed a reduction in psychosis symptoms compared to placebo, while the drug's safety profile was similar to that of the placebo group. These findings support advancing remlifanserin into larger, more definitive trials.
Psychosis in Alzheimer's—including delusions and hallucinations—is a common and distressing complication with limited approved therapies. Current options often carry significant side effects, especially for older adults. A treatment that effectively manages symptoms with a benign safety profile could address a major unmet need in dementia care, though further research is required to confirm these early results.
If confirmed in larger studies, remlifanserin could offer a new, well-tolerated option for Alzheimer's patients experiencing psychosis, potentially reducing caregiver burden and improving quality of life. However, phase 2 results do not guarantee success; the drug may still fail in later trials. Its impact would depend on regulatory approval, accessibility, and how it compares with existing treatments.